Furthermore, since elevated levels of both miR-142-3p and TNF at diagnosis seem to be a signature of disease activity as well as of a worse disease course and white matter damage, we suggest the potentiality of future personalised therapies possibly against both TNF and miR-142-3p to dampen inflammatory neurotoxic effects in MS. This evidence concerns the gene TNF and myeloid sarcoma.